Table 3.
Immunohistochemical staining of CRC samples and corresponding liver metastases
| Sr. No | TNM Classification | (a/b)CCR5 | (c)Liver metastases occurrence | |
|---|---|---|---|---|
| Primary tumor | Liver metastasis | |||
| 1 | pT3 pN1b (3/26), G2 | 5%, i1 | 30%, i1-2 | M |
| 2 | pT3 pN2b (10/19), G2 | 30%, i1-2 | 30%, i1 | M |
| 3 | pT4a pN2a (5/22), G3 | 60%, i1-2 | 10%, i1 | S |
| 4 | pT3 pN0 (0/11), G2 | 40%, i1 | 40%, i1 | S |
| 5 | pT3 pN0 (0/17), G2 | 10%, i1-2 | 0 | S |
| 6 | pT3 pN0 (0/21), G2 | 30%, i1-2 | 30%, i1 | M |
| 7 | ypT3m ypN2a (5/14), G(2)* | 30%, i1-2 | 70%, i1-2 | S |
| 8 | pT3 pN1b (2/8), G2 | 0 | 0 | M |
| 9 | pT3 pN2b (12/18), G2 | 5%, i1 | 30%, i1-2 | M |
| 10 | pT3 pN0 (0/20), G1 | 5%, i1-2 | 0 | M |
| 11 | pT4a pN2b (10/15), G2 | 0 | 0 | S |
| 12 | ypT3 ypN2a (4/18), G(2)* | 20%, i1-2 | 10%, i1 | M |
| 13 | pT3 pN0 (0/15), G2 | 80%, i2-3 | 5%, i1 | M |
| 14 | pT4a pN0 (0/21), G3 | 10%, i1-2 | 50%, i1 | M |
| 15 | ypT3 pN0, (0/10), G(2)* | 60%, i1-2 | 30%, i1 | M |
(a)Staining intensity: (i) 0 negative, 1 weak, 2 moderate, 3 strong
(b)Frequency of CCR5 positive tumor cells: isolated positive cells: < 10%; focally positive: 10–70%; diffusely positive: > 70%
(c)M: metachronous, S: synchronous
*Grading may not be applied as of neoadjuvant treatment